Insel Gruppe AG, University Hospital Bern
insel.chLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
731
Active
179
Phase 3
25
Total enrollment
1,441,218
Pipeline matrix
Showing 40 of 52 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| DOAC | — | — | — | — | 2 | ||
| Propofol | — | — | — | — | — | 3 | |
| Ketamine | — | — | — | — | — | 1 | |
| Hormone Replacement Therapy | — | — | — | — | — | 1 | |
| PVI using the PolarX Cryoballoon | — | — | — | — | — | 1 | |
| Landiolol | — | — | — | — | — | 1 | |
| Fremanezumab 225 Mg/1.5 mL Subcutaneous Solution | — | — | — | — | — | 1 | |
| Tenecteplase or Alteplase | — | — | — | — | — | 1 | |
| Tranexamic acid bolus 20 mg/kg | — | — | — | — | — | 1 | |
| Tranexamic acid bolus 10 mg/kg | — | — | — | — | — | 1 | |
| Tranexamic acid bolus 1 mg/kg | — | — | — | — | — | 1 | |
| Tranexamic acid continuous infusion of 1 mg/kg/h in the low dose group | — | — | — | — | — | 1 | |
| Gadobutrol | — | — | — | — | — | 1 | |
| Gadopiclenol | — | — | — | — | — | 1 | |
| dexmedetomidine to the standard treatment | — | — | — | — | — | 1 | |
| DOR/DTG/3TC | — | — | — | — | — | 1 | |
| P2Y12 inhibitor | — | — | — | — | — | 1 | |
| Aspirin | — | — | — | — | — | 1 | |
| Prednisone | — | — | — | — | — | 1 | |
| Empagliflozin 10 MG | — | — | — | — | — | 1 | |
| Methylprednisolone | — | — | — | — | — | 1 | |
| Prednisolone | — | — | — | — | — | 1 | |
| Melphalan | — | — | — | — | — | 2 | |
| Gemcitabin, Cisplatin and Durvalumab | — | — | — | — | — | 1 | |
| Vancomycin | — | — | — | — | — | 1 | |
| Indapamide 2.5 MG | — | — | — | — | — | 1 | |
| Hydrochlorothiazide 50Mg | — | — | — | — | — | 1 | |
| Chlorthalidone 25mg | — | — | — | — | — | 1 | |
| Tocilizumab before CAR-T cell | — | — | — | — | — | 1 | |
| Tocilizumab at emerging CRS | — | — | — | — | — | 1 | |
| Midazolam Nasal Spray 0.45 mg/spray | — | — | — | — | — | 1 | |
| Midazolam Nasal Spray 0.9 mg/spray | — | — | — | — | — | 1 | |
| Treosulfan | — | — | — | — | — | 1 | |
| AzaFol | — | — | — | — | — | 1 | |
| FDG | — | — | — | — | — | 1 | |
| Rivaroxaban 10 mg | — | — | — | — | — | 3 | |
| Apixaban 2.5 mg Oral | — | — | — | — | — | 1 | |
| Oxygen | — | — | — | — | — | 4 | |
| Dexamethasone | — | — | — | — | 2 | ||
| Metformin treatment | — | — | — | — | — | 1 |
12 more active programs hidden
Next readouts
- 2023-07-31
- 2025-06-30
- 2025-09
- 2025-12
- 2025-12-31
- 2026-03-27
- 2026-03-31
- 2026-06
- 2026-07
- 2026-07-01
Top conditions
- Coronary Artery Disease30
- Anesthesia14
- Stroke11
- Pain10
- Atrial Fibrillation10
- Ischemic Stroke10
- Multiple Sclerosis8
- Healthy8
Frequently asked questions about Insel Gruppe AG, University Hospital Bern
- How many clinical trials does Insel Gruppe AG, University Hospital Bern have on ClinicalTrials.gov?
- Insel Gruppe AG, University Hospital Bern is listed as the lead sponsor on 731 clinical trials in ClinicalTrials.gov, 179 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Insel Gruppe AG, University Hospital Bern's trials are in Phase 3?
- 25 of Insel Gruppe AG, University Hospital Bern's trials are in Phase 3, spread across 52 active drug programs.
- What therapeutic areas does Insel Gruppe AG, University Hospital Bern focus on?
- Insel Gruppe AG, University Hospital Bern's most-studied conditions on ClinicalTrials.gov are Coronary Artery Disease, Anesthesia, Stroke, Pain, Atrial Fibrillation.
- When are Insel Gruppe AG, University Hospital Bern's next clinical trial readouts?
- Insel Gruppe AG, University Hospital Bern has 10 upcoming primary-completion readouts tracked here; the soonest is “Comparison of PolarX and the Arctic Front Cryoballoons for PVI in Patients With Symptomatic Paroxysmal AF”, expected around 2023-07-31.